305.11
2.86 (0.95%)
| Previous Close | 302.25 |
| Open | 308.99 |
| Volume | 313,500 |
| Avg. Volume (3M) | 510,895 |
| Market Cap | 8,863,622,144 |
| Price / Earnings (TTM) | 23.52 |
| Price / Earnings (Forward) | 24.81 |
| Price / Sales | 4.37 |
| Price / Book | 14.88 |
| 52 Weeks Range | |
| Earnings Date | 21 Jul 2025 - 25 Jul 2025 |
| Profit Margin | 19.31% |
| Operating Margin (TTM) | 20.32% |
| Diluted EPS (TTM) | 13.09 |
| Quarterly Revenue Growth (YOY) | 9.30% |
| Quarterly Earnings Growth (YOY) | 11.70% |
| Total Debt/Equity (MRQ) | 25.33% |
| Current Ratio (MRQ) | 0.730 |
| Operating Cash Flow (TTM) | 581.97 M |
| Levered Free Cash Flow (TTM) | 433.28 M |
| Return on Assets (TTM) | 15.44% |
| Return on Equity (TTM) | 65.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | Medpace Holdings, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 3.0 |
| Average | 1.75 |
|
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the US, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 20.54% |
| % Held by Institutions | 91.81% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 355.00 (Mizuho, 16.35%) | Buy |
| Median | 328.00 (7.50%) | |
| Low | 300.00 (Truist Securities, -1.68%) | Hold |
| Average | 325.20 (6.59%) | |
| Total | 1 Buy, 4 Hold | |
| Avg. Price @ Call | 303.90 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 23 Apr 2025 | 313.00 (2.59%) | Hold | 290.54 |
| Truist Securities | 23 Apr 2025 | 300.00 (-1.67%) | Hold | 290.54 |
| 10 Apr 2025 | 333.00 (9.14%) | Hold | 282.33 | |
| TD Cowen | 14 Apr 2025 | 328.00 (7.50%) | Hold | 305.28 |
| Mizuho | 09 Apr 2025 | 355.00 (16.35%) | Buy | 302.56 |
| Leerink Partners | 24 Mar 2025 | 330.00 (8.16%) | Hold | 330.59 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 21 Apr 2025 | Announcement | Medpace Holdings, Inc. Reports First Quarter 2025 Results |
| 18 Mar 2025 | Announcement | Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |